{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 477002950
| IUPAC_name = Diphtheria toxin-Interleukin-2 fusion protein
| image = 
<!-- Clinical data -->
| tradename = Ontak
| Drugs.com = {{drugs.com|monograph|denileukin_diftitox}}
| MedlinePlus = a611024
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X --> C
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = Rx-only
| legal_status = 
| routes_of_administration = Intravenous
<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 70-80 min
| excretion = 
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 173146-27-5
| ATC_prefix = L01
| ATC_suffix = XX29
| ATC_supplemental = 
| PubChem = 
| IUPHAR_ligand = 7044
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00004
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 25E79B5CTM
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201550
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| C=2560 | H=4042 | N=678 | O=799 | S=17
| molecular_weight = 57647.3 g/mol
}}
'''Denileukin diftitox''' (trade name '''Ontak''') was an antineoplastic agent, an engineered protein combining [[Interleukin-2]] and [[Diphtheria toxin]].  Denikeukin diftitiox could bind to [[IL2 receptor|Interleukin-2 receptors]]<ref name="pmid17187516">{{cite journal |author=Turturro F |title=Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders |journal=Expert Rev Anticancer Ther |volume=7 |issue=1 |pages=11â€“7 |year=2007 |pmid=17187516 |doi=10.1586/14737140.7.1.11}}</ref> and introduce the diphtheria toxin into cells that express those receptors, killing the cells.  In some [[Leukemia]]s and [[Lymphoma]]s malignant cells express these receptors, so denileukin diftitox can target these. 

In 1999 Ontak was approved by the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA) for treatment of [[Cutaneous T-cell lymphoma]] (CTCL).<Ref name=FDA>FDA Page Last Updated: May 11, 2009 [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm095661.htm Changes in the Ontak (denileukin diftitiox) Package Insert to Include a Description of Ophthalmologic Adverse Events]</ref>  

There is some evidence tying it to vision loss and in 2006 the FDA added a [[black box warning]] to the drug's label.<ref name=FDA/>

In 2014 marketing of Ontak was discontinued in the US.<ref>{{cite web|title=FDA Drug Shortages|url=https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Denileukin+Diftitox+%28Ontak%29+Injection&st=d&tab=tabs-2|publisher=FDA|accessdate=3 July 2017|date=31 January 2014}}</ref>

==References==
{{Reflist}}

==External links==
* [http://www.fda.gov/medwatch/safety/2006/ONTAK_PI_3-1-06.pdf FDA Safety Alert]

{{Extracellular chemotherapeutic agents}}
{{Interleukin receptor modulators}}

[[Category:Antineoplastic drugs]]
[[Category:Diphtheria]]


{{antineoplastic-drug-stub}}